The CRO Encorium is looking to sell its assets from Encorium Group which is fully owned by Encorium Oy of Europe. In 2008, the revenue dropped significantly, along with the abrupt departure of two CEOs of the company.
Encorium CEO David Ginsberg stated in company statement:
"Over the last several months we have been actively pursuing opportunities to enhance and maximize stockholder value. Encorium's management and board have determined a sale of our assets was the best strategy to pursue. Both purchasers are well-respected organizations with strong management teams and therapeutic and regulatory expertise and we believe that transferring our assets in these two transactions is in the best interest not only for our stockholders, but for our customers and employees as well. These transactions will enable our project teams to remain wholly intact so as to continue to provide excellent service to our customers."
Source: Clinical Trials Today
Blog Archive
-
▼
2009
(173)
-
►
November
(8)
- Forced Degradation Brochure Now Available
- Call for Bloggers: Attend Partnerships in Clinical...
- Forced Degradation Forum Brochure Available
- Contract Research Remains Strong According to F&S ...
- A new way to find potential clinical trial partici...
- Partnerships In Clinical Trials Expands Its Global...
- Malaria vaccine trail to begin in east Africa
- Florida Senator wants to see clinical trial expens...
-
►
October
(8)
- PPD Makes Significant Inroad into China Biotech wi...
- Studies may be failing to show adverse effects of ...
- Genzyme begins Phase 3 clinical trial
- Amarin Appoints Medpace as CRO for Two Phase 3 Car...
- Top 5 Clinical Trial Partnering in Asia Pacific Qu...
- Kansas Cancer Center to Join Clinical Trials
- New guidance draft document for REMS
- Adaptive Clinical Trials Benefit Smaller Laborator...
-
►
September
(12)
- Indian drug market to grow to $20 bil in 2015
- Concern for Outsourced Drug Clinical Trials
- Partnerships APAC looks at clinical trials in the ...
- New Bill Might Boost Recruitment Rates for Rare Di...
- Are you interested in clinical trials taking place...
- Clinical trials for medical devices
- Where are Clinical Trials Being Conducted in the U...
- Archived Web Seminar: REMS, EU-RMP and FDAAA: Navi...
- Stem cell treatment fails clinical trial
- H1N1 vaccine trials effective
- Reminder: Free Web Seminar Next Week
- Albany hospital sees increase in cancer clinical t...
-
►
August
(16)
- Pfizer and Private Team Access Launch New Patient ...
- The lack of participation in clincial trials
- Official Call For Papers: Oncology Clinical Trial...
- Outsourcing of clinical trials expected to rise by...
- Pfizer to create online networking site for clinic...
- Medicare's Stance on Clinical Trials
- Medicare's Stance on Clinical Trials
- Stem cells for the heart in clinical trial
- Biopharma in India is Surging
- goBalto, Matchmaking for CROs and Drug Developers
- India Expected to Take Larger Share of Outsourcin...
- Clinical Trial Cost & Contract Management Agenda F...
- Web Seminar: REMS, EU-RMP and FDAAA: Navigating th...
- Repros Therapeutics Inc. halts clinical trial
- Outsourcing to grow 10% says WSHP
- USA and Europe team together to monitor clinical t...
-
▼
May
(15)
- As Sponsors increasingly look to CROs to provide e...
- Shifting Clinical Trial Environment
- Centralized patient recruitment
- Making the Business Case for Improving your Compar...
- Recession, stimulus bill open new doors for CROs
- Top Five States for Biotech Innovation
- ASKA Partners with International CROs
- Encorium looking for a buyer
- Phase III Clinical Trials
- Bio-Imiging Technologies and Phoenix Data Systems ...
- A Look at the 18th Annual Partnerships with CROs
- CASE STUDY: How Do Mergers, Acquisitions and Licen...
- Leveraging Relationship Structures to Optimize Spo...
- Outsourcing Clinical Trials in Emerging Regions: I...
- How to Make Change Part of Your Competitive Advant...
-
►
November
(8)














0 comments:
Post a Comment